

Immuno-informatics analysis to identify novel vaccine candidates and design of a multi-epitope based vaccine candidate against Theileria parasites

Anand Srivastava^{1*}, Prajna P. Kar¹

¹National Institute of Animal Biotechnology (NIAB), India

Submitted to Journal:
Frontiers in Immunology

Specialty Section:
Vaccines and Molecular Therapeutics

ISSN:
1664-3224

Article type:
Original Research Article

Received on:
12 Dec 2017

Accepted on:
06 Sep 2018

Provisional PDF published on:
06 Sep 2018

Frontiers website link:
www.frontiersin.org

Citation:
Srivastava A and Kar PP(2018) Immuno-informatics analysis to identify novel vaccine candidates and design of a multi-epitope based vaccine candidate against Theileria parasites. *Front. Immunol.* 9:2213. doi:10.3389/fimmu.2018.02213

Copyright statement:
© 2018 Srivastava and Kar. This is an open-access article distributed under the terms of the [Creative Commons Attribution License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution and reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

This Provisional PDF corresponds to the article as it appeared upon acceptance, after peer-review. Fully formatted PDF and full text (HTML) versions will be made available soon.

1 **Title**

2 ***Immuno-informatics analysis to identify novel vaccine candidates and design generation of***
3 ***a multi-epitope based vaccine candidate against *Theileria annulata* parasites***

4

5 **Running title: Multi-epitope based vaccine candidates against *Theileria annulata***

6 Prajna Parimita Kar¹, Anand Srivastava^{1*}

7 ¹National Institute of Animal Biotechnology (NIAB),

8

9 *Corresponding author:

10 Anand Srivastava

11 National Institute of Animal Biotechnology (NIAB)

12 D. No. 1-121/1, 4th & 5th Floors, Axis Clinicals Building,

13 Miyapur, Hyderabad, Telangana 500 049, India

14 Phone: +914023049412

15 Fax: +914023042740

16 Email: anand@niab.org.in

17

18 Key words: *Theileria*, immuno-informatics, multi-epitope vaccine, subunit vaccine

19

20 **Abstract:**

21 Theileriosis poses a serious threat to ruminants in tropical and subtropical countries. It is a tick-
22 borne disease, caused by an apicomplexan parasite, *Theileria*. The high disease burden in
23 animals causes huge economic losses to marginal farmers. Further, with increasing cases of
24 resistance to commonly used drugs, it is highly desirable to develop better and cost-effective
25 vaccines against theileriosis.~~The high disease burden in animals lead to huge economic losses,~~
26 ~~with increasing cases of resistance to commonly used drugs, there is a strong requisite for a cost-~~
27 ~~effective vaccine against theileriosis.~~ The only available vaccine, live attenuated parasite
28 vaccine, has many drawbacks and hence is unsuitable for controlling this disease. ~~The~~
29 ~~immuno~~-informatics has emerged as a useful tool in down selection of potential molecules for
30 vaccine development. In this study, we ~~have used~~used an immuno-informatics driven genome-
31 wide screening strategy to identify potential vaccine targets containing important and effective
32 dominant immunogens against *Theileria*. The proteome of *Theileria annulata* was screened for
33 proteins with probability of plasma membrane localization or GPI anchor. The ~~non-homologous~~
34 proteins non-homologous to the host (bovine) were selected and their antigenicity was analyzed.
35 The B-cell epitopes were identified in the selected proteins and ~~were~~ mapped in the modelled
36 structure of the proteins. A total of nineteen linear epitopes in twelve proteins, ~~which are~~ exposed
37 in the extracellular space and having the potential to induce protective antibodies were obtained.
38 Additionally, CTL epitopes ~~which are~~, peptides with 9-mer core sequence, were also identified,
39 modelled and docked with bovine MHC-I structures. The CTL epitopes showing high binding
40 energy with the bovine MHC-I were further engineered in silico to ~~design a putative~~form a
41 multi-epitope vaccine candidate against *Theileria* parasites. The docking studies and molecular
42 dynamics studies with the predicted multi-epitope vaccine candidate and modelled bovine TLR-4

43 ~~exhibited~~~~showed~~ strong binding energy, ~~which~~ ~~suggests~~ ings that the complex is stable and the
44 putative multi-epitope vaccine candidate can be a potentially good candidate for vaccine
45 development.

46

47 **Introduction:**

48 *Theileria* spp. are tick-borne protozoan parasites which belong to the subphylum apicomplexa
49 ~~which~~~~that~~ includes a number of other important pathogens such as *Plasmodium*, *Babesia*,
50 *Toxoplasma*, *Cryptosporidium* and *Eimeria* species. *Theileria* spp. are predominantly parasites of
51 ruminants and are transmitted transstadially to the host, ~~transstadially~~, by ticks (Bishop et al.,
52 2004; Sivakumar et al., 2014). These parasites cause huge economic loss to farmers in tropical
53 and subtropical countries. Among various species of these parasites, the ~~two~~ most important ones
54 include *T. parva* and *T. annulata*, which cause economically important diseases in cattle, east
55 coast fever and tropical theileriosis, respectively. *T. parva* is transmitted by *Rhipicephalus*
56 *appendiculatus* whereas *T. annulata* is transmitted by several species of *Hyalomma*.

57 The disease, theileriosis, is characterized by the lympho-proliferation of the host leucocytes after
58 invasion by the parasites (Irvin, 1987). Other symptoms include fever, lymph node enlargement
59 and anaemia. The untreated animal usually dies within 3-4 weeks of the infection. This disease
60 kills over million animals every year and significantly reduces the productivity of the cattle
61 (Norval et al., 1991; Gharbi et al., 2006). The cCurrent control measures for theileriosis include
62 the use of acaricides (for controlling vector), chemotherapy (drug such as buparavaquone) and
63 vaccination. Traditionally, control of tick infection has been performed by the application of
64 acaricides. However, it is effective only when performed at the community level and regularly

65 for a prolonged period. The indiscriminate use of acaricides ~~has been~~ leading to resistance in
66 tick, thus adding another dimension to the problem. The chemotherapy agents such as
67 parvaquone, buparvaquone and halofuginone are effective during the initial stages of infection
68 (McHardy et al., 1985). However, these chemotherapy agents are quite expensive and are not a
69 good choice for the marginal farmers. In addition, reports of development of resistance to these
70 chemotherapy agents ~~are~~ a matter of deep concern (Mhadhbi et al., 2010). The only available
71 vaccine for theileriosis is a live attenuated vaccine ~~which is effective for providing protection to~~
72 ~~vaccinated animal~~ (Pipano, 1966). However, this vaccine needs a cold chain for transportation
73 and storage which leads to a huge increase in its cost (approximately \$8–12 per dose). Further,
74 some vaccinated cattle, especially immunocompromised cattle, remain as a source of
75 transmission of parasites to other cattle (Maritim et al., 1989).

76 ~~In general,~~ the subunit/multi-epitope based vaccines ~~are generally~~ is considered to be safer as
77 compared to ~~a~~ a live attenuated vaccines (Kallerup, 2015). Also, the cost of production and
78 distribution of subunit/multi-epitope vaccine is ~~quite comparatively~~ low, hence ~~these~~ it would be
79 economical for the marginal farmers. Thus, developing a subunit and/or multi-epitope vaccine
80 for theileriosis, is ~~urgently required~~ highly desirable. However, the efforts to develop ~~the~~ subunit
81 vaccines against *T. annulata* and *T. parva* ~~till date~~ have not been successful till date (Nene and
82 Morrison, 2016).

83 ~~It is possible to develop~~ long-lasting immunity against *Theileria* can be developed in cattle by
84 repeated challenge them with *T. parva* and *T. annulata* sporozoites, ~~in cattle~~ by developing
85 neutralizing antibodies (Musoke et al., 1982). ~~Further,~~ these neutralizing antibodies recognize
86 the p67 protein of *T. parva* (Dobbelaere et al., 1984). ~~The immunization study~~ with recombinant
87 p67 antigen ~~has been~~ been shown to induce immunity in 50% of vaccinated cattle (Musoke et

88 al., 2005). Also, ~~in case of *T. annulata*~~, antibodies against parasite protein SPAG1 and Tams1 in
89 *T. annulata* blocks the invasion of leucocytes by sporozoite (Williamson et al., 1989; Boulter et
90 al., 1994; Boulter et al., 1998).

91 A large body of evidence indicates that cellular immunity also plays a major role in protection
92 against *T. annulata* and *T. parva*. The immunity can be adoptively transferred by CD8+, but not
93 CD4+ T cells from vaccinated animals. This strongly suggests that cytotoxic T lymphocytes
94 (CTL) play an important role in developing immunity against *Theileria* parasites (Taracha et al.,
95 1995a; Taracha et al., 1995b). Further, major histocompatibility complex (MHC) class I-
96 restricted CD8+ cells, the cytotoxic lymphocytes (CTLs), that target schizont-infected
97 lymphocytes also play a primary role in mediating immunity against *Theileria* in cattle
98 (MacHugh et al., 2009; Morrison, 2009).

99 The availability of comprehensive genomic, transcriptomic and proteomic datasets of *Theileria*
100 parasite have provided opportunities for *in silico* mining of novel candidates for vaccine design
101 (Gardner et al., 2005; Pain et al., 2005; Witschi et al., 2013). Immuno-informatics, which
102 integrates the transcriptomics and proteomics through advances in computational and molecular
103 immunological tools, has emerged as a new tool for identification of the target antigens for
104 vaccine development (Davies et al., 2007; Tomar and De, 2014; Backert and Kohlbacher, 2015).
105 Since the experimental methods are difficult and time-consuming, the immuno-informatics
106 approach can narrow down a vast number of potential molecules to be tested, thus increasing the
107 chance of finding better candidates. Numerous studies have shown that epitopes based vaccines
108 could be effective in elucidating protective immunity against various pathogens such as influenza
109 A, hepatitis B and C virus, *Leishmania* and *Shigella* (Sominskaya et al., 2010; Stanekova and
110 Vareckova, 2010; He et al., 2015; e Silva et al., 2016; Pahil et al., 2017). In this study, using

111 immunoe-informatics-driven vaccine target screening strategy, the available transcriptomic and
112 proteomic data for *Theileria* parasites were analyzed to predict proteins/epitopes for vaccine
113 development that could elicit protective humoral and cellular immune response. For an effective
114 humoral response, the antigen must be antigenic and should possess B-cell epitopes, and for
115 effective CTL response, the peptide must be presented by MHC-I to the T cell receptor. Thus,
116 the model antigens for developing subunit/multi-epitope vaccine against *Theileria* should either
117 possess B-cell epitopes or be displayed by MHC-I to CTLs. ~~U~~Here, using immuno-informatics,
118 we have identified ~~12~~twelve proteins containing ~~19~~nineteen epitopes which are likely to elicit the
119 humoral immune response. ~~We have further designed and constructed a~~ multi-epitope subunit
120 vaccine by combining CTL epitopes which have the potential to elicit the cellular immune
121 response against *Theileria* parasites (*T. annulata* and *T. parva*). The results provide a new
122 strategy for epitope-based vaccine development for *Theileria* parasites and indicate that
123 immuno-informatics could be an alternative strategy to rapidly discover potential new antigens
124 for subunit/multi-epitopes vaccine development against parasites.

125 **Materials and Methods**

126 A systematic workflow (Figure 1A) was generated for the identification of potential vaccine
127 candidates and construction of multi-epitope subunit vaccine against *Theileria* parasites (*T.*
128 *annulata* and *T. parva*) from the available transcriptomic/proteomic data (Gardner et al., 2005;
129 Pain et al., 2005; Witschi et al., 2013).

130 **Sequence retrieval and sub-cellular localization**

131 All protein sequences of *T. annulata* were retrieved from the National Centre for Biotechnology
132 Information (NCBI) database. The CD-HIT server was used to remove proteins having 90% or

133 more similarity. All the parameters recommended by the server were set to default (Huang et al.,
134 2010). The CELLO v.2.5 server was used for the identification of subcellular localization of all
135 the selected proteins. The plasma membrane proteins were selected with a confidence score of
136 ≥ 2 (Yu et al., 2006). Further, all the proteins were analyzed for the presence of signal peptide
137 sequence ~~using SignalP 4.1~~ and GPI anchor using SignalP 4.1 and PredGPI server respectively,
138 with default settings (Pierleoni et al., 2008; Petersen et al., 2011).

139 **Screening proteins non-homologous to the host and orthologous to *T. parva***

140 The selected plasma membrane proteins and proteins having both the signal sequence and GPI
141 anchor were further analyzed for screening the proteins which are non-homologous to the host,
142 *Bos taurus*, using BLASTp server (Altschul et al., 1990) with a cut-off E-value 0.005. Proteins
143 predicted with E-value more than 0.005 were ~~expected likely~~ to be non-homologous to *Bos*
144 *taurus* and ~~were~~ selected for further analysis. Further, an orthologous search between *T.*
145 *annulata* and *T. parva* ~~prediction was carried out using OrthoMCL tool to identify conserved~~
146 ~~orthologous proteins (Chen et al., 2007)~~. The query strategy was designed in such a way that the
147 average identity between two proteins ~~should would~~ be greater than 50%, and ~~is would be~~
148 specific only to *T. annulata* and *T. parva*.

149 **Antigenicity of proteins**

150 The selected proteins (non-homologous to *Bos taurus* and orthologous to *T. parva*) from the
151 previous step were analyzed for their immunogenicity ~~properties~~ using Vaxijen - v2
152 (Doytchinova and Flower, 2007). The vaxijen is based on an alignment-free approach for antigen
153 prediction using auto cross-covariance (ACC) transformation of protein sequences into uniform
154 vectors of principal amino acid properties. The classification by Vvaxijen is solely based on the

155 physicochemical properties of proteins. The threshold was kept to 0.5 to predict probable
156 antigenic and non-antigenic proteins.

157 **B-cell epitope prediction**

158 The prediction of B-cell epitopes for all the selected antigenic proteins from the
159 previous step was performed using BCPREDS server with 90% specificity (El-Manzalawy et al.,
160 2008). BCPREDS server (B-cell epitope prediction) is based on Support Vector Machine (SVM)
161 classifiers and the training data-set containing 701 linear B-cell epitopes from Bcipep database
162 and randomly-701 random non-B-cell epitopes from SwissProt sequence database.

163 Further, the proteins were analyzed for the presence of putative transmembrane domains,
164 exposed and intracellular region(s) using TMHMM server
165 (<http://www.cbs.dtu.dk/services/TMHMM/>) (Krogh et al., 2001). Finally, those epitopes which
166 were exposed to the extracellular surface of the cells, were selected for further analysis.

167 **Model building, refinement and stereochemistry analysis of B-cell protein**

168 The tertiary structure of the selected proteins which possess B-cell epitopes was built using
169 RaptorX which is a web portal for protein structure and function prediction (Kallberg et al.,
170 2012). RaptorX uses a threading-based modelling approach for model building. RaptorX server
171 predicts three-dimensional structures for protein sequences without close homologs in the
172 Protein Data Bank (PDB). RaptorX server can predict secondary and tertiary structures, contacts
173 solvent accessibility, disordered regions and binding sites. It can also assign some confidence
174 scores to indicate the quality of a predicted 3D model such as p-value for the relative global
175 quality, GDT (global distance test) and uGDT (un-normalized GDT) for the absolute global

176 quality, and modelling error at each residue. The selected epitopes were then mapped on the
177 structure using the information obtained from the TMHMM prediction.

178 **Prediction of T cell epitope(s) ~~prediction~~ and their specific MHC-I restriction element(s)**

179 The prediction of cytotoxic T-cell (CTL) epitopes was done using NetCTL 1.2 server (Larsen et
180 al., 2007). ~~Cytotoxic T-cell epitope (CTL) prediction was done using NetCTL 1.2 server (Larsen~~
181 ~~et al., 2005).~~ The threshold was set to 0.98 for high sensitivity and accuracy. All antigenic
182 proteins were analyzed for the presence of CTL epitopes. The CTL epitopes identified from the
183 previous step were further screened for bovine MHC-I restriction element identification using
184 HLAREstrictor 1.1 (Erup Larsen et al., 2011). All ~~seventy seven~~77 bovine MHC-1 alleles present
185 in the database were analyzed for their ability to bind to identified CTL epitopes and their
186 binding affinity ~~with~~for respective MHC-I allele was also calculated. ~~The~~The threshold for strong
187 binder (IC₅₀) was set to 50 and percentile rank was set to 0.5. ~~The~~The threshold for weak binder
188 (IC₅₀) was set to 500 and percentile rank was set to 2.

189 **Model building, refinement and stereochemistry analysis of bovine MHC-I**

190 The sequence of bovine MHC-I alleles namely BoLA-3*05101, BoLA-1*00901, and BoLA-
191 1*00902 were downloaded from the Immuno Polymorphism Database (IPD) (Robinson et al.,
192 2013). Since crystal structures s for these proteins were not present, a reliable model was built
193 using homology modelling. The best template for the homology modelling was obtained through
194 protein BLAST (pBLAST) against Protein Data Bank (PDB) and the three-dimensional model of
195 BoLA-MHC protein were built using modeller 9.19 (Webb, 2014). The generated model was
196 then refined by ModRefiner (Xu and Zhang, 2011) and stereochemistry analysis was done using
197 PROCHECK, a protein parameters analysis tool ~~PROCHECK~~ (Laskowski, 1993).

198 **Tertiary model prediction for CTL epitopes**

199 PEP-FOLD server was used to predict the three-dimensional structure of alleach CTL epitopes
200 (Shen et al., 2014). Five probable structures were predicted by this server. The structure having
201 the lowest energy model was selected as the final model for the respective epitope.

202 **Interaction studies between selected MHC-1 allele and CTL epitope**

203 The strong binders pairs of MHC-1 allele and CTL epitope obtained from HLA-restrictors were
204 then used for molecular docking studies using AutoDock vina (Trott and Olson, 2010). The
205 hydrogen atoms were added to the selected MHC-I alleles and the file was then converted to
206 pdbqt format for docking studies with the CTL epitopes. For BoLA-3*05101, grid was set to -
207 23.025, -15.521, -28.935 for X, Y and Z co-ordinates, respectively. The grid box for BoLA-
208 1*00901 was set to 60.708, 61.642, 26.373 for X, Y and Z co-ordinates, respectively. In the case
209 of BoLA-1*00902 the grid box for X, Y and Z was set to 58.68, 64.412, 33.956 co-ordinates,
210 respectively. The binding affinity of the ligands with its receptor was measured in kcal/mol.

211 **Building and characterization of the multi-epitope subunit vaccine**

212 All CTL epitopes selected after MHC-I restriction element analysis and interaction studies were
213 fused together with the help of a linker AAY to build a multi-epitope vaccine molecule. The
214 multi-epitope vaccine molecule thus obtained was analyzed for its non-homology to bovine (as
215 described earlier). The antigenic properties of the multi-epitopes vaccine candidate was
216 estimated by Vaxijen server (as described earlier). The allergenicity of the vaccine candidate was
217 evaluated using AlgPred (<http://crdd.osdd.net/raghava/algpred/>)(Saha and Raghava, 2006). The
218 physiochemical properties such as amino acid composition, theoretical pI, instability index etc.,

219 of the vaccine candidates were calculated by ProtParam (<http://web.expasy.org/protparam/>)
220 (Gasteiger, 2005).

221 **Structure characterization of the multi-epitope vaccine candidate and bovine TLR-4**

222 A template-based tertiary structure prediction of the multi-epitope vaccine candidate was carried
223 out by RaptorX server (Kallberg et al., 2012). ~~The Ffurther, the~~ refinement of modelled multi-
224 epitope vaccine candidate was done ~~by~~ using ModRefiner server as described previously (Xu and
225 Zhang, 2011) and stereochemistry analysis was done using ~~protein parameters analysis tool~~
226 PROCHECK (Laskowski, 1993).

227 The sequence of bovine TLR-4 was downloaded from UniProt. Since crystal structure for this
228 protein was not present, a reliable model was built using homology modelling. The best template
229 for homology modelling was obtained through BLASTp against PDB database. ~~Using a full~~
230 ~~length human TLR-4 as a template, Aa~~ three-dimensional model of bovine TLR-4 protein was
231 built ~~on modeller 9.19 using a full-length human TLR4 as a template using modeller 9.19~~. The
232 generated model was then refined by using ModRefiner and stereochemistry analysis was done
233 using ~~protein parameters analysis tool~~ PROCHECK.

234 **Molecular docking of multi-epitope vaccine candidate with bovine TLR-4 receptor**

235 The interaction studies between bovine TLR-4 and final subunit vaccine protein were carried out
236 with the help of a protein-protein docking server PatchDock (Schneidman-Duhovny et al., 2005).
237 The results were refined according to their binding score by FireDock server (Mashiach et al.,
238 2008).

239 Molecular dynamics simulation of bovine TLR-4 receptor with multi-epitope vaccine 240 candidate

241 To determine the stability of a protein-ligand ~~stability-complex~~ molecular dynamics (MD)
242 simulation study of the complex is an important ~~application tool~~. Molecular dynamics simulation
243 was carried out for the docked complex of the TLR-4 and multi-epitope vaccine protein for
244 100ns with a time integral of 2fs using Maestro software. The simulation was done with Single
245 Point Charge (SPC) water as a solvent model and 0.15M-~~of~~ NaCl buffer. The boundary
246 conditions ~~were~~ set to orthorhombic (a=b=c=10 Angstrom; alpha=beta=gamma=90°). The
247 isothermal-isobaric pressure (NPT) ensemble ~~were~~ set at ~~temperature-300K~~ (temperature) and 1
248 atm pressure. Nose-Hoover Thermostat method was used to maintain the temperature constant.
249 To examine the standard deviation and fluctuation of the backbone of the protein, the root mean
250 square deviation (RMSD) and root mean square fluctuation (RMSF) analysis were performed.

251 Results

252 Identification of plasma membrane and GPI anchored proteins of *Theileria parasite-* 253 *annulata*

254 A systematic workflow based on the immuno-informatics approach was designed to identify the
255 potential vaccine candidates which would elicit an effective antibody response and to
256 ~~design~~develop a multi-epitope based vaccine candidate which would generate effective cell-
257 mediated immune response against *T:heileria parasites-annulata* (Figure 1A). The first step in
258 this workflow was to screen for *T. annulata* proteins ~~which~~ having the potential to be localized
259 on the cell surface. ~~For this~~ The complete transcriptome/proteome of *T. annulata* comprising of
260 total 3783 protein sequences ~~were~~ downloaded from NCBI database for this purpose (Figure
261 1B). ~~From all the protein sequences,~~ The paralogous sequences with more than 90% similarity

262 were identified using CD-HIT server from all the protein sequences. Twenty-eight protein
263 sequences were removed as paralogs while remaining 3755 protein sequences were selected for
264 further analysis. The selected 3755 protein sequences were submitted to the CELLO sub-cellular
265 localization ~~server tool~~, to screen for the proteins predicted to be localized on the plasma
266 membrane. ~~CELLO is based on support vector machine (SVM) system to predict the probability~~
267 ~~distribution for possible localization of the protein.~~ The output of this software is in the form of
268 different numerical values as gives different confidence scores for predicting the probability of
269 localization of the proteins in the cell. ~~To get better stringency in screening of the plasma~~
270 ~~membrane proteins, the confidence score of 2 or better was fixed.~~ A total of 711 proteins
271 obtained with the confidence score greater than 2 were selected for further analysis (Figure 1B).

272 Further more, the criteria chosen for identification of proteins predicted to be localized on the
273 cell surface was that it should have a signal peptide along with a GPI anchor ~~sequence~~. All the
274 3755 protein sequences were screened for the presence of a signal peptide sequence and a GPI-
275 anchor ~~sequence~~. ~~From SignalP analysis, out of Only 390 out of the~~ 3755 proteins ~~only 390~~
276 ~~proteins~~ were found to possess a signal peptide sequence based on SignalP 4.1 analysis. From
277 PredGPI analysis, ~~for GPI anchors signal~~, only 49 proteins containing a GPI-anchors signal
278 ~~sequence~~ were obtained. Only 24 out of these 3755 proteins were predicted to contain a signal
279 peptide sequence as well as a GPI-anchor ~~signal sequence~~ (Figure 1B).

280 Ten out of these 24 proteins were also present in the plasma membrane analysis. After adding the
281 results from CELLO for proteins predicted to be localized at the plasma membrane protein, and
282 proteins having both the signal peptide sequence and the GPI-anchor signal sequence, finally
283 726 protein sequences were finally selected for further analysis (Figure 1B).

284 **Identification of antigenic *T. annulata* proteins non-homologous to *Bos taurus* and**
285 **orthologous to *T. parva* ~~and antigenic proteins of *T. annulata*~~**

286 All 726 protein sequences from previous analysis based on the cell surface localization were
287 analyzed for their non-homology to the host (*Bos taurus*) and orthology to *T. parva*. BLASTp
288 analysis against *Bos taurus* resulted in 443 proteins with E-value above 0.005. It is assumed that
289 these proteins are not present in the host (Figure 1B).

290 The OrthoMCL server was ~~used~~employed for searching the orthologous or conserved protein
291 between *T. annulata* and *T. parva*. ~~The criteria for orthologous protein selection was based on~~
292 ~~conservancy of the protein in both the species with an average identity of greater than 50%.~~ Out
293 of the 443 selected proteins ~~which are~~ non-homologous to *Bos taurus*, only 32 proteins were
294 found to be conserved and ~~only~~ present exclusively in *T. annulata* and *T. parva*. These 32
295 proteins were selected for further screening (Figure 1B).

296 All 32 protein sequences selected from the previous step were submitted to Vaxijen web server
297 to predict the antigenic properties of each protein. Vaxijen web server is an efficient tool for
298 predicting antigenic properties of proteins with an accuracy of 70% to 89%. ~~With the threshold~~
299 ~~of 0.5,~~ Out of the ~~thirty two~~32 protein sequences, only ~~twenty one~~21 protein sequences were
300 predicted as probable potent antigen with the threshold of 0.5 (Table S1, S2). ~~Out of 21 protein~~
301 ~~sequences,~~ fifteen out of 21 proteins sequences were found to be hypothetical.

302 **Potential proteins of *Theileria parasites*, *annulata* proteins for peptide/subunit vaccine**
303 **development**

304 B-cell epitopes are the antigenic determinants regions which are recognized by the specific
305 antibodies. The predicted antigenic proteins were then analyzed for 20 amino acid long the

306 linear B-cell epitopes ~~of twenty residue long~~. BCPREDS server was used to predict the probable
307 B-cell epitope and ~~to minimize chances of false positive~~, the specificity was kept at 90% or more
308 ~~to minimize chances of false positive~~. Four proteins, namely TA15480, TA21140, TA09756, and
309 TA13665, were predicted not to possess any B-cell epitope with the defined cut off value (Table
310 S3). The B-cell epitope must be exposed to the extracellular regions of the cell to be recognized
311 by the antibodies. ~~h~~Hence the remaining 17 proteins with putative transmembrane domains
312 were analyzed for the ~~transmembrane~~, exposed and buried inside regions using TMHMM server.
313 ~~Hence, rest 17 proteins were analyzed by TMHMM server~~ (Table S4). The tertiary structures of
314 all these proteins were built using RaptorX, ~~a web portal for protein structure and function~~
315 ~~prediction~~ and the exposed epitopes were mapped on the structure (Figure 2, Figure S1). Five
316 proteins, namely TA15965, TA05820, TA14950, TA15795 and TA12045, were found to have no
317 exposed B-cell epitopes, while the remaining 12 proteins ~~were found to contained~~ B-cell
318 epitopes ~~which were~~ exposed to the cell surface (Figure 2, Figure S2). ~~In these 12 proteins a~~
319 total of ~~nineteen~~ 19 B-cell epitopes were predicted in these 12 proteins (Table 1). Presence of
320 merozoite-piroplasm surface antigen (TA17050) which is one of the leading vaccine candidates
321 for the subunit vaccine against *T. annulata* (Gubbels et al., 2000) in our final list of 12 proteins;
322 validates ~~authenticate~~ the *in silico* analysis. TA17050 contains five B-cell epitopes with good
323 peptide score (more than 0.97 for all peptides) and an antigenic score of 0.5708. The remaining
324 11 proteins also ~~All other eleven proteins~~ are potentially good targets for the development of
325 subunit vaccine, especially TA09755 (FLPQTSRPSMGKKKGSFQLP-with peptide score 0.976)
326 ~~showed~~ exhibited the highest antigenic score (0.7931) ~~among all eleven proteins~~. Tpr-related
327 protein family member (TA13385), which is unique to the *Theileria* parasite, could also be
328 considered as a good target for developing a subunit vaccine. Eight other peptides from the list

329 with scores more than 0.99, could be ~~evaluated further tested~~ as potential peptide-based vaccine
330 candidates (Table 1).

331 **Identification of cytotoxic T cell epitopes specific to bovine MHC-I restriction element(s)**

332 The predicted 21 antigenic proteins were analyzed for ~~the cytotoxic T cell (CTL)~~ epitopes using
333 NetCTL server. A total of 179 CTL epitopes were predicted with a threshold value of 0.98
334 (Table S5). The CTL epitopes work in conjugation with the MHC-I present on the surface of
335 antigen presenting cells. Hence, using HLA-restrictors server, all the 179 CTL epitopes were
336 analyzed for their ability to be recognized by MHC-I restriction elements of *Bos taurus* and ~~to~~
337 ~~predict~~ the binding affinity of each CTL epitope with bovine MHC-I allele was predicted. Only
338 ~~eleven-11~~ proteins containing ~~twenty-seven~~27 epitopes were predicted to have showed strong
339 binding affinity (IC₅₀ value <50 and percentile rank ~~was also~~ below 0.5) with MHC-I molecules
340 (Table S6). ~~Twenty-two~~ ~~Out~~ of these ~~27~~27 predicted T-cell epitopes, ~~twenty-two epitopes were~~
341 predicted to have showed strong binding affinity with BoLA-3*05101, ~~fourteen-14 out of these~~
342 27 epitopes were predicted to have showed strong binding affinity with BoLA-1*00902, and
343 ~~nine out of these 27~~ epitopes were predicted to have showed strong binding affinity with
344 BoLA-1*00901. Although many more MHC-I molecules were obtained which were predicted to
345 have showed strong binding to selected CTLs, but only these ~~three~~ three MHC-I molecules (BoLA-
346 3*05101, BoLA-1*00902, and BoLA-1*00901) were predicted to have showed strong binding
347 affinity for multiple epitopes (Table S6).

348 **Molecular modelling and structure refinement of bovine MHC-I allele**

349 The tertiary structure of BoLA-3*05101 was predicted by Modeller 9.19 with bovine MHC-I
350 molecule N*01801 (BoLA-A11) (3PWU) as the template. BoLA-3*05101 showed 84% identity

351 with N*01801. The root mean square deviation (RMSD) between the structure of modelled
352 BoLA-3*05101 and structure obtained after refinement was found to be 0.489 Å. The predicted
353 tertiary structure of BoLA-3*05101 contained sed 47.64% coils, 21.05% helixes and 31.30% beta
354 strands. The Ramachandran plot of this modelled protein obtained by PROCHECK ~~tool~~
355 suggested that this was a highly reliable model (Figure S2).

356 Both BoLA-1*00902 and BoLA-1*00901 showed 76% and 86% identity, respectively with
357 cattle MHC-I N*01301 (2XFX'A') presenting an 11mer peptide from *T. parva* chain A. The
358 RMSD value of modelled BoLA-1*00902 and BoLA-1*00901 protein, before and after
359 refinement, was calculated to be 2.682 Å and 1.713 Å respectively. The predicted structure of
360 BoLA-1*00902 contained 48.74% coils, 23.4% helixes and 27.86% beta strands while the
361 predicted structure of BoLA-1*00901 was found to have 45.54% coils, 24.02% helixes and
362 30.44% beta strands. The Ramachandran plot of modelled proteins obtained by PROCHECK
363 ~~tool~~ showed that the modelled proteins were stable (Figure S2).

364 **Modelled bovine MHC-I interacts strongly with identified CTL epitopes**

365 ~~For generating immune response- i~~ It is necessary for the CTL epitopes to interact with the
366 respective MHC-I molecule with high binding affinity for generating specific immune response-.
367 In order to find the affinity between bovine MHC-I allele and identified CTL epitopepepitope,e
368 molecular docking studies were performed using AutoDock Vina. All ~~twenty-seven~~27 CTL
369 epitopes modelled using PepFold server were docked with their respective MHC allele. The
370 predicted CTL epitopes "FVAWFYKLY" and "FLYKRDLPY" ~~showed~~exhibited the highest
371 binding affinity of -7.4 kcal/mol while "ILFTISLHY" ~~exhibited~~showed the lowest binding
372 affinity of -5.5 kcal/mol with BoLA-N: 05101 MHC allele (Figure 3, Table 2). The predicted

373 CTL epitopes “FLYKRDLPY” showed highest binding affinity of -6.7 kcal/mol and
374 “IAFCIILYY” showed the lowest binding affinity of -5.1 kcal/mol with BoLA-N: 00901 MHC
375 allele. The predicted CTL epitopes “IAFCIILYY” ~~showed~~displayed the highest binding affinity
376 of -7.2 kcal/mol and “STIAMGLVY” ~~showed~~displayed the lowest binding affinity of -4.4
377 kcal/mol with BoLA-N: 00902 MHC allele.

378 Further, TA12045 contains the highest number of CTL epitopes which showed strong affinity to
379 ~~18~~eighteen bovine MHC-I. Another protein, TA16125, contains ~~4~~four CTL epitopes which
380 showed strong affinity to ~~12~~twelve bovine MHC-I (Table S6). Thus these proteins namely
381 TA15965, TA12045 and TA16125 can also be considered as good candidates ~~for~~of T cell-
382 mediated response against *Theileria ~~-annulata~~* parasites.

383 **DesignConstruction of multi-epitope subunit vaccine and prediction of allergenicity,** 384 **physiochemical and antigenic properties**

385 Based on the predicted binding affinity score of CTL epitope and bovine MHC-I restriction
386 element analysis, all the 2727 CTL epitopes were fused together with a linker “AAY” to form
387 the multi-epitope subunit vaccine molecule. The final vaccine was composed of 321 amino acid
388 residues. The allergenicity of the vaccine construct was predicted using AlgPred against BLAST
389 search on allergen representative peptides (ARPs). The result showed that the multi-epitopes
390 vaccine candidate would not act as is not an allergen. The molecular weight and theoretical pI of
391 this multi-epitope subunit vaccine candidate were calculated as 3.79 kDa and 6.75 respectively.
392 Based on the theoretical ~~According to~~ pI calculation this, the multi-epitope vaccine candidate
393 was found to be slightly acidic in nature. Further, the antigenicity of this potential vaccine

394 candidate ~~construct~~ was predicted to be 0.7286 as analyzed by Vaxijen server, suggesting that ~~the~~
395 ~~multi-epitope vaccine candidate~~ it would be antigenic in nature.

396 **Homology modelling and model refinement of bovine TLR-4 and multi-epitope vaccine** 397 **candidate**

398 The three dimensional model of the multi-epitope vaccine candidate was generated using the
399 RaptorX server as no template was found ~~against in the~~ PDB database. ~~Only one domain was~~
400 ~~predicted in the multi-epitope vaccine candidate by~~ the RaptorX server predicted only a single
401 domain for this multi-epitope vaccine candidate. The best template for the multi-epitope vaccine
402 candidate was found to be 4AV3'A' with its p-value $6.61e^{-05}$ (Figure 4A). The Ramachandran
403 plot of this protein revealed that 89.1% amino acids were located in the core region, 8.3% amino
404 acids were located in the allowed region, 1.6% amino acids were located in the generously
405 allowed region and none was located in the disallowed region (Figure 4C). The predicted
406 secondary structure of the multi-epitope vaccine candidate was found to possess only helices
407 (Figure S3A).

408 As the crystal structure of bovine TLR-4 was not available, the tertiary structure of bovine TLR-
409 4 was modelled using 4G8A (human TLR-4) as a template by Modeller 9.19 software (Figure
410 5A). Both the query coverage and identity were found to be 72%. The structure was then
411 refined using ModRefiner and validated with PROCHECK analysis. The Ramachandran plot of
412 the modelled bovine TLR-4 revealed that 79.6% amino acids were located in the core region,
413 17.4% amino acids were located in the allowed region, 1.8% amino acids were located in the
414 generously allowed region and only 1.2% amino acids were located in the disallowed region.

415 **Multi-epitope vaccine candidate ~~does not possess~~ bovine CTL and B-cell epitopes specific**
416 **to Theileria parasites but not to the bovine host**

417 The analysis for the presence of CTL epitopes in the multi-epitope vaccine protein by the
418 NetCTL server showed the presence of a total of ~~forty nine~~49 CTL epitopes. Out of ~~the forty~~
419 ~~nine~~49 epitopes, ~~twenty six~~26 epitopes were found to be the same as the previously predicted
420 epitopes in our analysis (Table S7). ~~Remainingst~~ ~~twenty three~~23 epitopes were the newly
421 predicted CTL epitopes. All the newly predicted CTL epitopes were subjected to BLASTp
422 against bovine for non-homology search and it was found that none of ~~the these peptide~~epitopes
423 were present in the bovine. Further, the discontinuous B-cell epitopes were also predicted from
424 the structure of the multi-epitope vaccine protein using EliPro server (Ponomarenko et al., 2008).
425 A total of 9~~nine~~ conformational B-cell epitopes were predicted by the server (Figure 4B, Table
426 S8, Figure S3B). Similar to the CTL epitopes, all the predicted B-cell epitopes were also
427 analyzed for ~~their~~-non-homology to the bovine and it was found that none of ~~these~~se B-cell
428 epitopes were present in the bovine proteome database. These results suggest that ~~theis~~ potential
429 multi-epitope vaccine protein is non-homologous to bovine and does not possess any predicted
430 B-cell and CTL ~~predicted~~ epitopes from bovine. Hence, the putative multi-epitope vaccine
431 candidate would not generate an autoimmunity or tolerance in bovine.

432 **Molecular docking of the multi-epitope vaccine candidate with bovine TLR-4 receptor**

433 To ~~identify-predict the~~ binding energy of this multi-epitope vaccine candidate with the bovine
434 TLR-4, docking of this multi-epitope vaccine candidate with TLR-4 was carried out using
435 PatchDock server ~~which is~~ based on the shape complementarity principle (Figure 5B).
436 PatchDock server generated 20~~twenty~~ complexes which were scored according to the protein

437 surface, geometry and electrostatic complementarity. ~~In order to refine and re-score the docking~~
438 ~~solutions of TLR-4 and multi-epitope vaccine candidate,~~ The top ten complexes were then
439 submitted to the FireDock server in order to refine and re-score the docking solutions of TLR4
440 and multi-epitope vaccine candidate. The ~~F~~final docking model was chosen from the molecular
441 docking studies based on the binding score. The best structure of the multi-epitope vaccine
442 candidate and bovine TLR-4 showed a binding energy of -18.3 kcal/mol (Figure 5B). The
443 attractive van der Waals force was calculated as -36.97 kcal/mol, the repulsive van der Waals
444 force was 49.96 kcal/mol, and the atomic contact energy was -2.10.

445 **Molecular dynamics simulation of TLR-4 receptor with multi-epitope vaccine**

446 The evaluation of the stability of the bovine TLR-4 and multi-epitope vaccine candidate complex
447 using molecular dynamics showed that the complex was quite stable in SPC water type with
448 0.15M NaCl. The root mean square deviation (RMSD) of the backbone of the protein and the
449 root mean square fluctuation (RMSF) for all the side chain amino acid residues were analyzed
450 for a time period of 100ns. The interaction between the TLR-4 and the multi-epitope vaccine
451 protein was found to be stable after 10ns (Figure 6A). The RMSF of side chain residues was
452 found to be in between 1\AA^0 to 3\AA^0 with a little variation (Figure 6B). A total of ~~forty-two~~42
453 hydrogen bonds were formed between the TLR-4 receptor and the multi-epitope vaccine protein.
454 The simulation analysis clearly shows that the multi-epitope vaccine protein can be recognized
455 by the TLR-4 and ~~with~~ form a stable complex.

456 **Discussion:**

457 Various ~~One of the few~~ factors contributing to the ~~of~~ failure of ~~the any~~ antigen as a vaccine
458 candidate under development stages are ~~due to:~~ (a) antigen not being exposed to immune

459 response ~~and~~, (b) poor antigenic/immunogenicity response of antigen and, allergenicity to the
460 host. Recently, with the advancement of *in-silico* analysis it has been possible to identify
461 molecule(s) which would likely possess maximum qualities/properties to qualify as of a good
462 antigen. The primary aim of this study was to identify the candidate gene(s) ~~which have~~ ing the
463 potential to induce an immune response against macroschizont stage of *T. annulata*. ~~In this study~~
464 ~~w~~We utilized a systematic immuno-informatics in this study approach to predict potential
465 vaccine candidate(s) in ~~Theileria-annulata~~ parasites using the proteome databases of *T. annulata*
466 and *T. parva*, to ~~design~~ develop a multi-epitope based vaccine.

467 One ~~of the~~ important criteria for selecting a potential antigen for vaccine development is that it
468 should be located on the surface of the cell so that it is more accessible for both the humoral and
469 the cellular immune system. The proteins are translocated to the cell surface using a signal
470 sequence for plasma membrane translocation or could be anchored to the
471 Glycosylphosphatidylinositol (GPI) moieties. These proteins which are exposed to the
472 extracellular surface are easily recognized and are likely to elicit an immune response when
473 used as ~~the~~ a target antigen for ~~a~~ vaccine development. ~~Therefore, the putative~~ proteins from the
474 *Theileria* proteome database were thus examined for their translocation to plasma membrane
475 using CELLO software. CELLO is based on support vector machine (SVM) system to predict
476 the probability distribution for possible localization of the protein in ~~win~~. ~~Prediction of cellular~~
477 ~~localization by CELLO is much~~ high is more reliable than the other sub-localization prediction
478 tool, ~~such as~~ PSORTb. ~~Furthermore, PSORTb program is trained only for the bacterial~~
479 proteome (Gardy et al., 2005). We selected a confidence score of 2 or more for the sub
480 localization prediction based on our observation that in many cases the values lesser than 2
481 resulted in predicting two different sub-localizations for the same protein. ~~Proteins after~~

482 ~~removing duplicates, were predicted for subcellular localization.~~ A total of 711 proteins were
483 predicted to be localized at the cell surface using the CELLO prediction server. To take into
484 account the proteins ~~Further, the proteins that~~ may also be present ~~on~~ at the cell surface using GPI
485 moieties. ~~We~~ we first looked for the proteins ~~which h~~ having signal ~~sequence~~ peptide sequences
486 using the SignalP 4.1 server. Few research groups have also analysed the proteome of *T.*
487 *annulata* and *T. parva* for the identification of proteins containing signal peptide sequence and
488 GPI anchor using the older version of SignalP (Pain et al., 2005; Weir et al., 2009; Woods et al.,
489 2013; Bilgic et al., 2016). However, number of false positives in SignalP 4.1 is lesser compared
490 to the older versions (www.cbs.dtu.dk/services/SignalIP/performance.php). SignalP 4.1 uses a
491 Hidden Markov Model (HMM) method for predicting the presence of signal peptide in the
492 protein. However, it does not predict the GPI anchors unlike the previous versions. PredGPI
493 server was used to identify the GPI anchored proteins in our study. ~~In order to identify those~~
494 ~~proteins which may be GPI anchored, PredGPI server was used.~~ The PredGPI uses a prediction
495 method which is coupled to HMM and SVM methods. PredGPI has been shown to outperform
496 the other methods used for ~~to~~ predicting GPI-anchors as it has a lower rate of false positive
497 predictions with respect to the other available methods (Pierleoni et al., 2008). Only 22 ~~twenty~~
498 ~~two~~ proteins were predicted to possess both the signal peptide and GPI anchor. The putative
499 plasma membrane and the GPI anchored proteins obtained from both the analysis were added for
500 further analysis.

501 In order to generate an immune response, the antigen must be recognized as non-self. Hence, the
502 antigen for which homologous protein is present in the host is not considered a good candidate
503 for vaccine development. Thus, we removed all the proteins homologous to *Bos taurus* in our
504 study. ~~Out of 733,~~ only 443 out of the 733 proteins were predicted ~~to be~~ as non-homologous to

505 *Bos taurus*. Further, an ideal vaccine candidate should be capable of stimulating an effective
506 immune response against various species of *Theileria*. Thus, to increase the stringency, the query
507 was set in such a way that only *T. annulata* or *T. parva* proteins ~~are~~would be screened.

508 Antigenicity is one of the important features of an antigen for vaccine development. Vaxijen is
509 the only server which uses alignment-independent prediction of protective antigens. It classifies
510 antigen based on the physiochemical properties of the proteins. The prediction efficiency of this
511 methods is found to be 70-80%. We finally found 21 ~~Only twenty one~~ proteins which were
512 predicted as antigenic and also were found to be antigenic which qualified other screening
513 conditions.

514 An effective vaccine should induce a specific immune response against specific
515 pathogens/antigen by selectively stimulating antigen-specific B-cells or CTLs or T helper cells.
516 In order to initiate the humoral response, antigens must be exposed and should be recognized by
517 the naive B-cells. Further, to initiate the cellular response, naive T cells need to be primed by the
518 peptide antigens bound to the major histocompatibility ~~complex~~proteins (MHC) molecules on
519 the antigen presenting cells (APCs). The activation of CTLs (CD8+ cells) is a result of the
520 specific engagement of a 9 mer peptide to the MHC-I proteins. The CTLs eliminate the cells
521 which they recognize as non-self, hence the immune system must be able to discriminate
522 between healthy and infected cells.

523 Thus, ~~the~~ identify B-cell epitopes were predicted using the ~~BCPREDS server was used~~.
524 Further, B-cell epitopes must be accessible to the immune response. H, ~~hence~~ all the proteins
525 containing B-cell epitopes were modelled and the epitopes ~~were~~ mapped on the structure. Four
526 proteins did not show any B-cell epitopes and epitopes on ~~five~~ 5 other proteins were not

527 accessible to immune recognition. Finally, ~~11~~eleven proteins were ~~found~~predicted to be good
528 targets for the development of subunit vaccine. One of the ~~11~~eleven proteins was TA17050
529 which is one of the leading vaccine candidates, thus suggesting the likeliness of the other ~~10~~ten
530 proteins ~~could also~~be good candidates for subunit vaccine development.

531 The CTL epitopes in all the antigenic proteins were identified using NetCTL server. NetCTL is a
532 quite reliable tool for the prediction of cytotoxic T lymphocytes and ~~theirs~~ predictions done by
533 this isare based on proteasomal cleavage, Transporter associated with antigen presentation (TAP)
534 transport efficiency and MHC class I affinity. In comparison to the earlier version NetCTL1.0,
535 the accuracy of prediction of cytotoxic T lymphocytes using NetCTL server is significantly
536 improved (Larsen et al., 2007). Although NetCTL is a tool designed for the prediction of human
537 CTL epitopes in a given protein, it can be used for bovine as well with equal efficiency. A total
538 of ~~179~~one hundred and seventy nine CTL epitopes were identified using this prediction method.
539 Previously, studies conducted to identify CTL epitopes from *T. parva* specific CD8+ T cell line
540 by transfecting cells with parasite cDNA identified ~~ten~~10 *T. parva* antigens having a total of
541 ~~fifteen~~15 CTL epitopes (Graham et al., 2006). It was initially intriguing to observe that Nnone
542 of the antigens identified as CTL epitopes by this group were present in our analysis. However,
543 aAfter careful analysis, we found that the 10 proteins that this study identified did not possess
544 either a none of the proteins from which these CTL epitopes were identified, did not either
545 possess plasma membrane or signal sequence and GPI anchor together, sequenceor they were not
546 predicted to be localized to the plasma membrane. Using a similar strategy, three proteins
547 (TA15705, TA17545 and TA14970) were shown to be recognized by CD8 T cells from T.
548 annulata infected cattle (MacHugh et al., 2011). TA14970 neither contains a signal sequence nor
549 a GPI anchor. Although, TA15705 (Ta9) and TA17545 possess the signal sequence, but these

550 proteins lack a GPI anchor. Hence, we did not include these proteins in our further analysis. The
551 CTL epitopes must be presented by MHC-I on the surface of the antigen presenting cells to the
552 T-cell receptor for the activation of cell-mediated response. Hence, we ~~predicted-calculated~~ the
553 binding energy of these CTL epitopes with all the bovine MHC-I molecules using HLA restrictor
554 server. The binding pairs which showed the highest energy were selected for further analysis.
555 Three MHC-I molecules, namely BoLA-3*05101, BoLA-1*00902 and BoLA-1*00901, were
556 found to be the best, both in terms of binding energy and recognition to multiple CTL epitopes.
557 Hence these three molecules were further modelled to predict their three-dimensional structures.
558 Protein models having more than 90% of the residues in the core and allowed regions are
559 generally considered as high-quality models. ~~W~~~~Hence,~~ we found that the predicted model for
560 BoLA-3*05101, BoLA-1*00902, and BoLA-1*00901 were high-quality models based upon the
561 presence of more than 90% of their amino acid residues in the core and allowed regions. The
562 docking of selected CTL epitopes with modelled BoLA-3*05101, BoLA-1*00902 and BoLA-
563 1*00901 further confirmed the stability of the complex. Thus, ~~twenty seven~~²⁷ CTL epitopes
564 were found to be potential peptides for generating effective CTL response. Immunization with all
565 these twenty-seven, 9 mer peptides for the generation of CTL response would be a tedious
566 process. ~~H~~~~ence~~ we ~~designed-engineered~~ a new protein containing all the CTL epitopes joined
567 with AAY linker. Immunization with a single protein (approximately 3.79 kDa) would be much
568 easier and cost effective if it could generate an effective cellular response. Thus, we re-analyzed
569 our newly designed ~~again analyzed~~ multi-epitope vaccine candidate for its ability to serve as an
570 ideal vaccine candidate. The newly designed engineered molecule was ~~predicted~~^{found} to be non-
571 allergic while it ~~but~~ was antigenic in nature. The multi-epitope vaccine candidate was found to

572 possess ~~49~~forty-nine CTL epitopes and none of them ~~were~~as found to be present in the bovine,
573 and ~~twenty-six~~26 were specifically from ~~Theileria-annulata~~parasites.
574 Since the multi-epitope vaccine candidate is a novel protein, hence no template was found for
575 homologous modelling. ~~Accordingly~~Thus, ~~RaptorX~~APTORX was used for generating a model
576 for this protein. The possibility of the generated model being worse than the best of a set of
577 randomly generated models can be calculated by p-value. ~~The~~lesser p-value represents the
578 higher-quality model. For the alpha helix protein p-value should be lesser than 10^{-3} , and for the
579 beta-sheet protein p-value should be lesser than 10^{-4} . The predicted structure of the multi-
580 epitope subunit vaccine contained all alpha helices with a p-value of $6.61e^{-05}$ which indicate
581 that the structure predicted by RaptorX is a high-quality model. The un-normalized Global
582 Distance Test (uGDT) also estimate the model quality, like, if a protein contains greater than
583 ~~100~~hundred residues and if the uGDT score is more than 50, it is a good indicator for high
584 quality model. The final multi-epitope ~~subunit~~vaccine candidate had the ~~contained~~uGDT score
585 of 73. ~~Forty~~four percent of the protein residues ~~were~~are exposed in the subunit vaccine protein,
586 ~~while and it is generally assumed was reported t~~hat if 15% of the protein residues are exposed
587 and solvent accessible, they can generate effective humoral and cellular immune response.

588 The modelled tertiary structure of this multi-epitope vaccine candidate suggests that the protein
589 is quite stable and ordered. ~~Further~~more, none of the discontinuous B-cell epitopes of the multi-
590 epitope vaccine protein were from bovine, suggesting that the new molecule would not generate
591 any self-immune response to bovine.

592 The effective CTL response ~~would be generated~~against the multi-epitope vaccine candidate
593 would be generated only when it is presented to the CD8+ T cells by the antigen presenting cells.

594 The Toll-like receptors (TLRs) which are evolutionarily conserved proteins can sense foreign
595 molecules. They are characterized by an extracellular leucine-rich repeat domain and an
596 intracellular Toll/IL-1 receptor-like (TIR) domain. ~~The~~ TLRs play a fundamental role in the
597 initiation of ~~the~~ immune response to ~~the~~ infectious agents through their recognition of ~~the~~
598 conserved microbial molecular pattern. Out of all ~~the~~ TLRs, only TLR4 and TLR11 have been
599 shown to recognize ~~the~~ proteins (review (Takeuchi and Akira, 2010)). TLR-11 is absent in both
600 human and bovine, thus in our *in silico* analysis we tested the binding ability of multi-epitope
601 vaccine candidate with TLR-4 ~~only, for which~~ ~~We~~ we performed homologous modelling ~~offor~~
602 bovine TLR-4 using human TLR-4 as a template. The binding energy of ~~the designed~~ multi-
603 epitope vaccine candidate and bovine TLR-4 was ~~predicted found~~ to be -18.3 kcal/mol and ~~the~~
604 binding sites in the protein ~~were~~ distributed to ~~the~~ various regions of the proteins, suggesting
605 that ~~the~~ bovine TLR-4 would effectively recognize ~~the~~ vaccine candidate ~~designed herein~~. Thus
606 overall in this study, we ~~designedengineered~~ a new vaccine candidate *in silico* containing
607 multiple epitopes of ~~Theileia parasites. annulata.~~

608 **Conclusions:**

609 ~~In conclusion,~~ this study shows that the immuno-informatics driven genome-wide screening of
610 vaccine targets for *Theileria* is ~~a~~ highly promising strategy to accelerate vaccine development for
611 this parasite. Based on this strategy, B-cell epitopes and CTLs were mapped from the proteome
612 of the *Theileria* parasite. This study provides ~~a~~ comprehensive analysis of *Theileria* proteins
613 predicted to be better protective immunogens with high conservancy ~~and~~, which would have ~~the~~
614 potential for eliciting both neutralizing antibodies and T-cell responses. Thus, this study opens
615 new avenues for accelerating vaccine development by providing various potential molecules as
616 novel vaccine candidates and a multi-epitope based vaccine candidate.

617 Reference:

- 618 Altschul, S.F., Gish, W., Miller, W., Myers, E.W., and Lipman, D.J. (1990). Basic local alignment search tool.
619 *J Mol Biol* 215(3), 403-410. doi: 10.1016/S0022-2836(05)80360-2.
- 620 Backert, L., and Kohlbacher, O. (2015). Immunoinformatics and epitope prediction in the age of genomic
621 medicine. *Genome Med* 7, 119. doi: 10.1186/s13073-015-0245-0.
- 622 Bilgic, H.B., Karagenc, T., Bakirci, S., Shiels, B., Tait, A., Kinnaird, J., et al. (2016). Identification and Analysis
623 of Immunodominant Antigens for ELISA-Based Detection of *Theileria annulata*. *PLoS One* 11(6),
624 e0156645. doi: 10.1371/journal.pone.0156645.
- 625 Bishop, R., Musoke, A., Morzaria, S., Gardner, M., and Nene, V. (2004). *Theileria*: intracellular protozoan
626 parasites of wild and domestic ruminants transmitted by ixodid ticks. *Parasitology* 129 Suppl,
627 S271-283.
- 628 Boulter, N., Knight, P.A., Hunt, P.D., Hennessey, E.S., Katzer, F., Tait, A., et al. (1994). *Theileria annulata*
629 sporozoite surface antigen (SPAG-1) contains neutralizing determinants in the C terminus.
630 *Parasite Immunol* 16(2), 97-104.
- 631 Boulter, N.R., Brown, C.G., Kirvar, E., Glass, E., Campbell, J., Morzaria, S., et al. (1998). Different vaccine
632 strategies used to protect against *Theileria annulata*. *Ann N Y Acad Sci* 849, 234-246.
- 633 Davies, M.N., Guan, P., Blythe, M.J., Salomon, J., Toseland, C.P., Hattotuwigama, C., et al. (2007). Using
634 databases and data mining in vaccinology. *Expert Opin Drug Discov* 2(1), 19-35. doi:
635 10.1517/17460441.2.1.19.
- 636 Dobbelaere, D.A., Spooner, P.R., Barry, W.C., and Irvin, A.D. (1984). Monoclonal antibody neutralizes the
637 sporozoite stage of different *Theileria parva* stocks. *Parasite Immunol* 6(4), 361-370.
- 638 Doytchinova, I.A., and Flower, D.R. (2007). VaxiJen: a server for prediction of protective antigens, tumour
639 antigens and subunit vaccines. *BMC Bioinformatics* 8, 4. doi: 10.1186/1471-2105-8-4.
- 640 e Silva, R.d.F., Ferreira, L.F.G.R., Hernandez, M.Z., de Brito, M.E.F., de Oliveira, B.C., da Silva, A.A., et al.
641 (2016). Combination of In Silico Methods in the Search for Potential CD4(+) and CD8(+) T Cell
642 Epitopes in the Proteome of *Leishmania braziliensis*. *Front Immunol* 7, 327. doi:
643 10.3389/fimmu.2016.00327.
- 644 El-Manzalawy, Y., Dobbs, D., and Honavar, V. (2008). Predicting linear B-cell epitopes using string kernels.
645 *J Mol Recognit* 21(4), 243-255. doi: 10.1002/jmr.893.
- 646 Erup Larsen, M., Klopperpris, H., Stryhn, A., Koofhethile, C.K., Sims, S., Ndung'u, T., et al. (2011).
647 HLArestrictor--a tool for patient-specific predictions of HLA restriction elements and optimal
648 epitopes within peptides. *Immunogenetics* 63(1), 43-55. doi: 10.1007/s00251-010-0493-5.
- 649 Gardner, M.J., Bishop, R., Shah, T., de Villiers, E.P., Carlton, J.M., Hall, N., et al. (2005). Genome sequence
650 of *Theileria parva*, a bovine pathogen that transforms lymphocytes. *Science* 309(5731), 134-137.
651 doi: 10.1126/science.1110439.
- 652 Gardy, J.L., Laird, M.R., Chen, F., Rey, S., Walsh, C.J., Ester, M., et al. (2005). PSORTb v.2.0: expanded
653 prediction of bacterial protein subcellular localization and insights gained from comparative
654 proteome analysis. *Bioinformatics* 21(5), 617-623. doi: 10.1093/bioinformatics/bti057.
- 655 Gasteiger, E.H., C.; Gattiker, A.; Duvaud, S.; Wilkins, MR.; Appel, RD.; Bairoch, A.; (2005). *Protein*
656 *Identification and Analysis Tools on the ExPASy Server*. Humana Press.
- 657 Gharbi, M., Sassi, L., Dorchies, P., and Darghouth, M.A. (2006). Infection of calves with *Theileria annulata*
658 in Tunisia: Economic analysis and evaluation of the potential benefit of vaccination. *Vet Parasitol*
659 137(3-4), 231-241. doi: 10.1016/j.vetpar.2006.01.015.
- 660 Graham, S.P., Pelle, R., Honda, Y., Mwangi, D.M., Tonukari, N.J., Yamage, M., et al. (2006). *Theileria parva*
661 candidate vaccine antigens recognized by immune bovine cytotoxic T lymphocytes. *Proc Natl Acad*
662 *Sci U S A* 103(9), 3286-3291. doi: 10.1073/pnas.0511273103.

663 Gubbels, M.J., Katzer, F., Hide, G., Jongejan, F., and Shiels, B.R. (2000). Generation of a mosaic pattern of
664 diversity in the major merozoite-piroplasm surface antigen of *Theileria annulata*. *Mol Biochem*
665 *Parasitol* 110(1), 23-32.

666 He, L., Cheng, Y., Kong, L., Azadnia, P., Giang, E., Kim, J., et al. (2015). Approaching rational epitope vaccine
667 design for hepatitis C virus with meta-server and multivalent scaffolding. *Sci Rep* 5, 12501. doi:
668 10.1038/srep12501.

669 Huang, Y., Niu, B., Gao, Y., Fu, L., and Li, W. (2010). CD-HIT Suite: a web server for clustering and comparing
670 biological sequences. *Bioinformatics* 26(5), 680-682. doi: 10.1093/bioinformatics/btq003.

671 Irvin, A.D.a.M., W.I (1987). *Immunopathology, immunology and immunoprophylaxis of Theileria*
672 *infections*. Florida CRC Press, Boca Raton

673 Kallberg, M., Wang, H., Wang, S., Peng, J., Wang, Z., Lu, H., et al. (2012). Template-based protein structure
674 modeling using the RaptorX web server. *Nat Protoc* 7(8), 1511-1522. doi:
675 10.1038/nprot.2012.085.

676 Kallerup, R.S.a.F., C. (2015). *Classification of Vaccines* Springer.

677 Krogh, A., Larsson, B., von Heijne, G., and Sonnhammer, E.L. (2001). Predicting transmembrane protein
678 topology with a hidden Markov model: application to complete genomes. *J Mol Biol* 305(3), 567-
679 580. doi: 10.1006/jmbi.2000.4315.

680 Larsen, M.V., Lundegaard, C., Lamberth, K., Buus, S., Lund, O., and Nielsen, M. (2007). Large-scale
681 validation of methods for cytotoxic T-lymphocyte epitope prediction. *BMC Bioinformatics* 8, 424.
682 doi: 10.1186/1471-2105-8-424.

683 Laskowski, R.M., MW.; Moss, DS.; Thornton, JM. (1993). PROCHECK - a program to check the
684 stereochemical quality of protein structures. *J. App. Cryst.* 26, 283-291.

685 MacHugh, N.D., Connelley, T., Graham, S.P., Pelle, R., Formisano, P., Taracha, E.L., et al. (2009). CD8+ T-
686 cell responses to *Theileria parva* are preferentially directed to a single dominant antigen:
687 Implications for parasite strain-specific immunity. *Eur J Immunol* 39(9), 2459-2469. doi:
688 10.1002/eji.200939227.

689 MacHugh, N.D., Weir, W., Burrells, A., Lizundia, R., Graham, S.P., Taracha, E.L., et al. (2011). Extensive
690 polymorphism and evidence of immune selection in a highly dominant antigen recognized by
691 bovine CD8 T cells specific for *Theileria annulata*. *Infect Immun* 79(5), 2059-2069. doi:
692 10.1128/IAI.01285-10.

693 Maritim, A.C., Young, A.S., Lesan, A.C., Ndungu, S.G., Mutugi, J.J., and Stagg, D.A. (1989). Theilerial
694 parasites isolated from carrier cattle after immunization with *Theileria parva* by the infection and
695 treatment method. *Parasitology* 99 Pt 1, 139-147.

696 Mashiach, E., Schneidman-Duhovny, D., Andrusier, N., Nussinov, R., and Wolfson, H.J. (2008). FireDock: a
697 web server for fast interaction refinement in molecular docking. *Nucleic Acids Res* 36(Web Server
698 issue), W229-232. doi: 10.1093/nar/gkn186.

699 McHardy, N., Wekesa, L.S., Hudson, A.T., and Randall, A.W. (1985). Antitheilerial activity of BW720C
700 (buparvaquone): a comparison with parvaquone. *Res Vet Sci* 39(1), 29-33.

701 Mhadhbi, M., Naouach, A., Boumiza, A., Chaabani, M.F., BenAbderazzak, S., and Darghouth, M.A. (2010).
702 In vivo evidence for the resistance of *Theileria annulata* to buparvaquone. *Vet Parasitol* 169(3-4),
703 241-247. doi: 10.1016/j.vetpar.2010.01.013.

704 Morrison, W.I. (2009). Progress towards understanding the immunobiology of *Theileria* parasites.
705 *Parasitology* 136(12), 1415-1426. doi: 10.1017/S0031182009990916.

706 Musoke, A., Rowlands, J., Nene, V., Nyanjui, J., Katende, J., Spooner, P., et al. (2005). Subunit vaccine
707 based on the p67 major surface protein of *Theileria parva* sporozoites reduces severity of infection
708 derived from field tick challenge. *Vaccine* 23(23), 3084-3095. doi: 10.1016/j.vaccine.2004.09.039.

709 Musoke, A.J., Nantulya, V.M., Buscher, G., Masake, R.A., and Otim, B. (1982). Bovine immune response to
710 *Theileria parva*: neutralizing antibodies to sporozoites. *Immunology* 45(4), 663-668.

711 Nene, V., and Morrison, W.I. (2016). Approaches to vaccination against *Theileria parva* and *Theileria*
712 *annulata*. *Parasite Immunol* 38(12), 724-734. doi: 10.1111/pim.12388.

713 Norval, R.A., Lawrence, J.A., Young, A.S., Perry, B.D., Dolan, T.T., and Scott, J. (1991). *Theileria parva*:
714 influence of vector, parasite and host relationships on the epidemiology of theileriosis in southern
715 Africa. *Parasitology* 102 Pt 3, 347-356.

716 Pahil, S., Taneja, N., Ansari, H.R., and Raghava, G.P.S. (2017). In silico analysis to identify vaccine
717 candidates common to multiple serotypes of *Shigella* and evaluation of their immunogenicity.
718 *PLoS One* 12(8), e0180505. doi: 10.1371/journal.pone.0180505.

719 Pain, A., Renauld, H., Berriman, M., Murphy, L., Yeats, C.A., Weir, W., et al. (2005). Genome of the host-
720 cell transforming parasite *Theileria annulata* compared with *T. parva*. *Science* 309(5731), 131-133.
721 doi: 10.1126/science.1110418.

722 Petersen, T.N., Brunak, S., von Heijne, G., and Nielsen, H. (2011). SignalP 4.0: discriminating signal peptides
723 from transmembrane regions. *Nat Methods* 8(10), 785-786. doi: 10.1038/nmeth.1701.

724 Pierleoni, A., Martelli, P.L., and Casadio, R. (2008). PredGPI: a GPI-anchor predictor. *BMC Bioinformatics*
725 9, 392. doi: 10.1186/1471-2105-9-392.

726 Pipano, E., Tsur, I. (1966). Experimental Immunization against *Theileria annulata* with a tissue culture
727 vaccine I. Laboratory trails *Refu Vet.* 23, 186-194.

728 Ponomarenko, J., Bui, H.H., Li, W., Fussedder, N., Bourne, P.E., Sette, A., et al. (2008). ElliPro: a new
729 structure-based tool for the prediction of antibody epitopes. *BMC Bioinformatics* 9, 514. doi:
730 10.1186/1471-2105-9-514.

731 Robinson, J., Halliwell, J.A., McWilliam, H., Lopez, R., and Marsh, S.G. (2013). IPD--the Immuno
732 Polymorphism Database. *Nucleic Acids Res* 41(Database issue), D1234-1240. doi:
733 10.1093/nar/gks1140.

734 Saha, S., and Raghava, G.P. (2006). AlgPred: prediction of allergenic proteins and mapping of IgE epitopes.
735 *Nucleic Acids Res* 34(Web Server issue), W202-209. doi: 10.1093/nar/gkl343.

736 Schneidman-Duhovny, D., Inbar, Y., Nussinov, R., and Wolfson, H.J. (2005). PatchDock and SymmDock:
737 servers for rigid and symmetric docking. *Nucleic Acids Res* 33(Web Server issue), W363-367. doi:
738 10.1093/nar/gki481.

739 Shen, Y., Maupetit, J., Derreumaux, P., and Tuffery, P. (2014). Improved PEP-FOLD Approach for Peptide
740 and Mini-protein Structure Prediction. *J Chem Theory Comput* 10(10), 4745-4758. doi:
741 10.1021/ct500592m.

742 Sivakumar, T., Hayashida, K., Sugimoto, C., and Yokoyama, N. (2014). Evolution and genetic diversity of
743 *Theileria*. *Infect Genet Evol* 27, 250-263. doi: 10.1016/j.meegid.2014.07.013.

744 Sominskaya, I., Skrastina, D., Dislers, A., Vasiljev, D., Mihailova, M., Ose, V., et al. (2010). Construction and
745 immunological evaluation of multivalent hepatitis B virus (HBV) core virus-like particles carrying
746 HBV and HCV epitopes. *Clin Vaccine Immunol* 17(6), 1027-1033. doi: 10.1128/CVI.00468-09.

747 Stanekova, Z., and Vareckova, E. (2010). Conserved epitopes of influenza A virus inducing protective
748 immunity and their prospects for universal vaccine development. *Virology* 7, 351. doi:
749 10.1186/1743-422X-7-351.

750 Takeuchi, O., and Akira, S. (2010). Pattern recognition receptors and inflammation. *Cell* 140(6), 805-820.
751 doi: 10.1016/j.cell.2010.01.022.

752 Taracha, E.L., Goddeeris, B.M., Morzaria, S.P., and Morrison, W.I. (1995a). Parasite strain specificity of
753 precursor cytotoxic T cells in individual animals correlates with cross-protection in cattle
754 challenged with *Theileria parva*. *Infect Immun* 63(4), 1258-1262.

755 Taracha, E.L., Goddeeris, B.M., Teale, A.J., Kemp, S.J., and Morrison, W.I. (1995b). Parasite strain specificity
756 of bovine cytotoxic T cell responses to *Theileria parva* is determined primarily by
757 immunodominance. *J Immunol* 155(10), 4854-4860.

- 758 Tomar, N., and De, R.K. (2014). Immunoinformatics: a brief review. *Methods Mol Biol* 1184, 23-55. doi:
759 10.1007/978-1-4939-1115-8_3.
- 760 Trott, O., and Olson, A.J. (2010). AutoDock Vina: improving the speed and accuracy of docking with a new
761 scoring function, efficient optimization, and multithreading. *J Comput Chem* 31(2), 455-461. doi:
762 10.1002/jcc.21334.
- 763 Webb, B., Sali, A. (2014). *Comparative Protein Structure Modeling Using Modeller*. John Wiley & Sons, Inc.
- 764 Weir, W., Sunter, J., Chaussepied, M., Skilton, R., Tait, A., de Villiers, E.P., et al. (2009). Highly syntenic and
765 yet divergent: a tale of two Theilerias. *Infect Genet Evol* 9(4), 453-461. doi:
766 10.1016/j.meegid.2009.01.002.
- 767 Williamson, S., Tait, A., Brown, D., Walker, A., Beck, P., Shiels, B., et al. (1989). Theileria annulata
768 sporozoite surface antigen expressed in Escherichia coli elicits neutralizing antibody. *Proc Natl
769 Acad Sci U S A* 86(12), 4639-4643.
- 770 Witschi, M., Xia, D., Sanderson, S., Baumgartner, M., Wastling, J.M., and Dobbelaere, D.A. (2013).
771 Proteomic analysis of the Theileria annulata schizont. *Int J Parasitol* 43(2), 173-180. doi:
772 10.1016/j.ijpara.2012.10.017.
- 773 Woods, K.L., Theiler, R., Muhlemann, M., Segiser, A., Huber, S., Ansari, H.R., et al. (2013). Recruitment of
774 EB1, a master regulator of microtubule dynamics, to the surface of the Theileria annulata schizont.
775 *PLoS Pathog* 9(5), e1003346. doi: 10.1371/journal.ppat.1003346.
- 776 Xu, D., and Zhang, Y. (2011). Improving the physical realism and structural accuracy of protein models by
777 a two-step atomic-level energy minimization. *Biophys J* 101(10), 2525-2534. doi:
778 10.1016/j.bpj.2011.10.024.
- 779 Yu, C.S., Chen, Y.C., Lu, C.H., and Hwang, J.K. (2006). Prediction of protein subcellular localization. *Proteins*
780 64(3), 643-651. doi: 10.1002/prot.21018.

781

782 **Figure ligands:**

783 Figure 1. (A) Systematic workflow for identification of potential vaccine candidates and
784 construction of multi-epitope subunit vaccine against *Theileria annulata* from the available
785 proteomic data. n, represent total number of proteins used for analysis.

786 ¹<https://www.ncbi.nlm.nih.gov/>;

787 ²<http://weizhong-lab.ucsd.edu/cdhit-web-server/cgi-bin/index.cgi?cmd=cd-hit>;

788 ³<http://cello.life.nctu.edu.tw/>;

789 ⁴<http://gpcr.biocomp.unibo.it/predgpi/pred.htm>;

790 ⁵<http://www.cbs.dtu.dk/services/SignalP/>;

791 ⁶ <https://blast.ncbi.nlm.nih.gov/Blast.cgi?PAGE=Proteins>

792 ⁷ [http://orthomcl.org/orthomcl/;](http://orthomcl.org/orthomcl/)

793 ⁸ <http://www.ddg-pharmfac.net/vaxijen/VaxiJen/VaxiJen.html;>

794 ⁹ [http://ailab.ist.psu.edu/bcpred/;](http://ailab.ist.psu.edu/bcpred/)

795 ¹⁰ <http://raptorx.uchicago.edu/>

796 ¹¹ [http://www.cbs.dtu.dk/services/NetCTL/;](http://www.cbs.dtu.dk/services/NetCTL/)

797 ¹² [http://www.cbs.dtu.dk/services/HLArestrictor/;](http://www.cbs.dtu.dk/services/HLArestrictor/)

798 ¹³ <http://mobylye.rpbs.univ-paris-diderot.fr/cgi-bin/portal.py#forms::PEP-FOLD3;>

799 ¹⁴ Modeller9.19;

800 ¹⁵ AutodockVina;

801 ¹⁶ [https://bioinfo3d.cs.tau.ac.il/PatchDock/;](https://bioinfo3d.cs.tau.ac.il/PatchDock/)

802 (B) Number of proteins obtained after various analysis. a. total proteins of *T. annulata*, b.
803 proteins after removal of duplicates, c. plasma membrane proteins, d. proteins containing GPI
804 anchor & signal peptide, e. proteins which are non-homologous to bovine, f. orthologous
805 proteins specifically present in *T. annulata* and *T. parva*, g. antigenic proteins

806 **Figure 2.** Molecular modelling of antigenic proteins of *Theileria annulata* containing B-cell
807 epitope using RAPTOR X. (A) Ta 09755, (B) Ta 13065, (C) Ta 13810, (D) Ta 13385, and (E) Ta
808 16735. Identified epitopes mapped onto the modelled proteins are shown in red color, for buried
809 epitopes, and blue color, for exposed epitopes using TMHMM.

810 **Figure 3.** Representative model of interaction between predicted CTL epitope through molecular
811 docking studies (A) FLYKRDLPY with BoLA-N:05101, binding energy -7.8 kcal/mol, (B)
812 FLYKRDLPY with BoLA-N:00902, binding energy = -7.7 kcal/mol, (C) WMVFFIVVY with
813 BoLA-N:00901, binding energy = -7.6 kcal/mol. Red represent epitope, blue represent modelled
814 bovine MHC-I and red represent CTL epitope.

815 **Figure 4.** Modelled structure of multi-epitope based subunit vaccine candidate: (A) Three
816 dimensional model of multi-epitope based subunit vaccine candidate obtained by homologous
817 modelling and refinement. The red color represents CTL epitopes and gray color represents AAY
818 linker, (B) B-cell epitopes of multi-epitope based subunit vaccine candidate represented in green
819 color, (C) Ramachandran plot analysis of the multi-epitope based subunit vaccine candidate
820 showing favored (91.7%), allowed (4.8%), generously allowed (2.6%) and disallowed (1%)
821 regions.

822 **Figure 5.** Docking studies of multi-epitope vaccine candidate and modelled bovine TLR-4: (A)
823 Three dimensional model of bovine TLR-4 obtained by homologous modelling and refinement,
824 (B) Docked complex of TLR-4 and multi-epitope based subunit vaccine candidate, (C) Binding
825 sites of multi-epitope vaccine candidate with bovine TLR-4. The interacting residues of the
826 putative both multi-epitope vaccine candidate and bovine TLR-4 are presented as surface
827 model, colored in green sphere.

828 **Figure 6.** Molecular dynamics simulation study of TLR-4 and multi epitope vaccine protein
829 complex. (A) Root Mean Square Deviation (RMSD) with a time duration of 100ns, grey line
830 represent side-chain and black line represent backbone of the protein chain (B) Root mean
831 Square Fluctuation (RMSF) of the docked complex side-chain with a time duration of 100ns.

832 **Table 1.** Antigenic proteins with peptide score and antigenic score

833 **Table 2.** Interaction studies with modelled bovine MHC-I with CTL epitopes

834 **Supplementary figures**

835 **Figure S1** (A) Molecular modelling of antigenic proteins of *Theileria annulata* containing B-cell
836 epitope using RAPTOR X. The red color represent buried epitopes and blue represent exposed
837 using TMHMM, (B) Ramachandran plot analysis of modelled antigenic proteins of *T. annulata*
838 containing B-cell epitope using RAPTOR X.

839 **Figure S2** Ramachandran plot analysis of bovine MHC-I alleles predicted by Modeller 9.19
840 showing that all the predicted model are high quality model with more than 90% residue are in
841 core region. (A) BoLA-3*05101 (B) BoLA-1*00901 (C) BoLA-1*00902.

842 **Figure S3** (A) Secondary structure of multi-epitope vaccine protein shows 90% residue are
843 helix, 9% residue are coil and no beta sheet are present in the structure (B) Conformational B-
844 cell epitope in the multi-epitope vaccine protein predicted by EliPro server. The multi-epitope
845 vaccine protein was represented in red color with ribbon model. There are nine conformational
846 B-cell epitope are present in the final multi-epitope subunit vaccine protein showed in different
847 color with surface model.

848 **Supplementary Table**

849 **Table S1:** Annotation of antigenic proteins. (XLSX)

850 **Table S2:** Antigenic protein prediction using Vaxijen server with threshold 0.5. (XLSX)

851 **Table S3:** B-cell epitope prediction using BCPREDS with specificity 90%. (XLSX)

852 **Table S4:** Analysis of epitopes present in cytoplasm, transmembrane and extracellular regions
853 using TMHMM server. (XLSX)

854 **Table S5:** T cell epitope prediction using NetCTL with a threshold of 0.98. (XLSX)

855 **Table S6:** Identification of MHC-I restriction elements. (XLSX)

856 **Table S7:** Identification of CTL epitopes generated in multi-epitope vaccine candidate. (XLSX)

857 **Table S8:** Identification of B-cell epitopes generated in multi-epitope vaccine candidate.
858 (XLSX)

859

Provisional

860 Table 1: Antigenic proteins with peptide score and antigenic score

S. No.	Gene ID	Position	Peptide sequence	Peptide Score	Antigenic Score	
862	1	TA09755	132	FLPQTSRPSMGKKKGSFQLP	0.976	0.7931
	2	TA13065	157	KKPASDFEEQALEEYLKDKD	0.964	0.7595
	3	TA13810	193	DEKEETSKKKYVLMVVVVVV	0.972	0.7115
863	4	TA13385	336	AVGFPSITENWDSTAATGNG	0.993	0.6889
			375	EYKRHDPSKWPTDGMTTRTA	0.985	
864	5	TA16735	912	VNWEYVWEKEYKYRMMKMSN	0.986	0.6443
	6	TA17050	16	VISSVNAANEDEKKKEEKD	1	
			105	NLHPAQPKMFKKKGDKEYSE	1	
865			212	FYTGDSRLKETYFELKDDKW	0.994	0.5708
			243	LNAMNSSWSTDYKPVVDKFS	0.991	
866			43	TSCENVTFKNVDSNTTELV	0.978	
	7	TA11900	198	ELTTTKLVNVIVNGTQESIN	0.984	0.578
	8	TA13820	24	EKNEQVTIDINKDATNPRKN	0.985	0.5741
867	9	TA17055	175	HTVERDDESEEEAAITRVCC	0.999	0.5708
			39	LGYTLDTTIITSIGRDKINR	0.986	
868	10	TA16125	99	NVTEGGTSMYKYFVKVKGKW	0.963	0.5466
	11	TA21100	32	YNSTQNDTNPRTGSYYNAV	0.999	0.5342
869	12	TA12115	251	FINFICKIIPPGFPGQLLIQ	1	0.5083
			37	LVKKTLFNRETDPSNNNFPF	0.963	

870

871

872

873

874

875

876

877

878 Table 2: Interaction studies with modelled bovine MHC-I with CTL epitopes


Interaction studies with BoLA-N:05101 and CTL epitopes		
MHC-I	CTL epitopes	Binding energy (Kcal/mol)
BoLA-N:05101	LYEYVLYLY	-5.8
	FVAWFYKLY	-7.4
	FSNLYSGYY	-6.7
	FLYKRDLPY	-7.4
	IAFCIILYY	-6.9
	FINLTLTY	-6.4
	ITDVLIIYY	-6.8
	ILLTFNHLY	-7.1
	ILFTISLHY	-5.5
	CSLYFVVLY	-6.3
	KMGHLTIYY	-6.4
	STIAMGLVY	-6.5
	SSFNILLSY	-6.4
	FINLVHYYY	-6.2
	FTEHNSLEY	-6.6
	YSLLFFYLY	-5.8
	SLLFFYLYY	-6.9
	FALDIMTKY	-5.7
	YIKEYFSLY	-7.1
	VVFDYSVKY	-5.5
VFSIVSSLY	-6.5	
FFELLPSLY	-6.7	

Interaction studies with BoLA-N:00901 and CTL epitopes		
MHC-I	CTL epitopes	Binding energy (Kcal/mol)
	LVLVGSLSY	-5.6
	FLYKRDLPY	-6.7
	WMVFFIVVY	-6.4
	IAFCIILYY	-5.1
BoLA-N:00901	KMGHLTIYY	-6.6
	STIAMGLVY	-5.6
	SSFNILLSY	-6.6
	YLLFFYLY	-6.3
	VVDYSVKY	-5.6

Interaction studies with BoLA-N:00902 and CTL epitopes		
MHC-I	CTL epitopes	Binding energy (Kcal/mol)
	LVLVGSLSY	-6
	FLYKRDLPY	-6.8
	WMVFFIVVY	-6.1
	IAFCIILYY	-7.2
	ILLTFNHLY	-4.8
	KLVNLILLY	-5.6
BoLA-N:00902	MVIAVLSHY	-6.1
	ILFTISLHY	-6.3
	KMGHLTIYY	-6
	STIAMGLVY	-4.4
	SSFNILLSY	-5.6
	YLLFFYLY	-5.9
	LLVNHTYHY	-5.5
	VVDYSVKY	-6.5

905

Figure 1



B.




Figure 2




Figure 3




Figure 4




Figure 5.




Figure 6

